Abstract
Abstract Peritoneal carcinomatosis (PC) is the most frequent mode of recurrence and metastasis in gastric cancer (GC). Apart from being potentially lethal, PC poses multiple complexities hindering cancer directed treatment, such as bowel obstruction, bowel perforation with bowel fistulae, nutritional deprivation and intractable malignant ascites; all of which finally culminate into agonizing death with immeasurable suffering. Recognition of PC as locoregional rather than a systemic disease has opened a treatment gateway where cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) are now increasingly utilized in the treatment pathways. In this review, we take a contemporary view on the management of gastric cancer at risk of PC or gastric cancer presenting with PC. We highlight the rationale of intraperitoneal chemotherapy and drugs used, followed by different scenarios and different modalities of intraperitoneal chemotherapy in light of the available literature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
